Global Humanized Mouse and Rat Model Market Forecast to 2022
April 16, 2018 | PRNewswireEstimated reading time: 2 minutes
The humanized mouse models market is projected to reach $128.9 Million by 2022 from $80.3 Million in 2017, at a CAGR of 9.9% during the forecast period. The humanized rat models market is expected to reach $8.9 Million by 2022 from $5.9 Million in 2017, at a CAGR of 8.4% during the forecast period.
The key factors boosting market growth are increasing number of R&D activities in pharmaceutical and biotechnology companies, increasing number of research activities involving humanized models, continuous support in the form of investments and grants from the government and private sectors, and growing demand for personalized medicine.
By type, the humanized mouse models market is segmented into genetic and cell-based humanized mouse models. In 2017, the genetic models segment accounted for the largest share of the humanized mouse models market. The factors contributing to the large share of this segment include its widespread use in compound analysis and biological efficacy & safety testing.
Furthermore, the cell-based humanized mouse models is categorized into CD34, PBMC, and BLT humanized mouse models. In 2017, the CD34 models segment accounted for the largest share of the cell-based humanized mouse models market and is expected to register the highest growth rate during the forecast period.
The major factors driving the growth of this market are usage of CD34 mouse models in in-vivo platforms for analyzing the safety and effectiveness of potential new drugs that can modulate the immune system. They are used for long-term studies in the fields of immuno-oncology, infectious disease, and graft versus host disease. Thus, the growing application areas of CD34 models are expected to trigger the demand for these models in the coming years.
By application, the humanized mouse models market is segmented into oncology, immunology and infectious diseases, neuroscience, hematopoiesis, toxicology, and other applications. The oncology segment is estimated to grow at the highest CAGR owing to factors such as increasing research activities and growing funding from various governments to carry out research studies on cancer.
By end user, the humanized mouse models market is segmented into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. The pharmaceutical & biotechnology companies segment accounted for the largest share of the humanized mouse models market in 2017. However, the contract research organizations (CROs) segment of the market is projected to grow at the highest CAGR during the forecast period. Increasing number of pharmaceutical companies outsourcing their preclinical studies to contract research organizations (CROs) is one of the factors contributing to the growth of this segment.
Suggested Items
Mycronic Releases Interim Report January–March 2024
04/18/2024 | MycronicNet sales increased 39 percent to SEK 1,692 (1,219) million. Based on constant exchange rates, net sales increased 42 percent.
Real Time with... IPC APEX EXPO 2024: Exploring Silicone Solutions with R&D Director of CHT
04/17/2024 | Real Time with...IPC APEX EXPOIn this interview, Gerry Ellis, the R&D director for CHT, discusses the product range offered by his company. He explains the challenges in creating base formulations, the drive to make products more user-friendly, and the various application techniques involved. Ellis also highlights the key market segments and the significance of providing efficient solutions to customers.
Gartner Forecasts Worldwide IT Spending to Grow 8% in 2024
04/17/2024 | Gartner, Inc.Worldwide IT spending is expected to total $5.06 trillion in 2024, an increase of 8% from 2023, according to the latest forecast by Gartner, Inc. This is an increase from the previous quarter’s forecast of 6.8% growth and puts worldwide IT spending on track to surpass $8 trillion well before the end of the decade.
Catching Up With Chasom Electronics
04/16/2024 | Dan Beaulieu, D.B. Management GroupI recently met with Chasom Electronics’ founding director Anil Kumar. Chasom offers a unique menu of services for companies looking to extend their technology capabilities on a short- or long-term basis. Read on to learn about this very unique service company.
Cicor Records Solid Growth in Q1
04/16/2024 | CicorThe Cicor Group continued to grow in the first three months of the year. Quarterly sales increased by 11.8% to CHF 107.3 million compared to the first quarter of the previous year (Q1/2023: CHF 96.0 million).